Clinical trials are an important part of the Food and Drug Administration’s (FDA) approval process for bringing new medications and treatments to the market, so patients have access to them. Frequently, this research requires participation by patients who are willing to be test subjects to determine if a new drug, process, piece of equipment, or other therapy is safe for use by humans, has the intended effect on the disease, and what adverse effects might arise.
One of the challenges of trying to find new treatments for rare diseases is finding enough people who meet the requirements of the clinical trial. This is why TMA encourages those with myositis diseases who qualify for trials to seriously consider this opportunity to further the science that can benefit all myositis patients. TMA members who have been involved in past clinical trials highly recommend it as a way to further knowledge of rare diseases like myositis.
This chart lists clinical trials that are currently seeking research subjects to test medications for myositis diseases and their complications.
This chart lists research projects seeking patients who are willing to serve as subjects by providing information and submitting to examinations so scientists can better understand myositis diseases and their impact on patients and families.
Find information about these and other clinical trials here. You can search by specific drug name and/or disease (dermatomyositis, polymyositis, necrotizing myopathy, inclusion body myositis, juvenile myositis, antisynthetase syndrome).
TMA also has available a number of peer-reviewed published research articles on our website.
Understanding clinical trials: Necessary steps for clinical development – Presentation by Dr. Conrad “Chris” Weihl at TMA’s Annual Patient Conference
ResearchMatch is a free online recruitment and education platform designed to promote the completion of clinical trials by matching people interested in research with researchers throughout the United States. Funded by the National Institutes of Health’s National Center for Advancing Translational Sciences, ResearchMatch is disease-neutral and institution-neutral so that participants with and without health problems can be included and valued.
Get involved. Get Matched!
Find an update here from Orphazyme to address Frequently Asked Questions about how COVID-19 is impacting the Arimoclomol trial